AbbVie Inc (ABBV.K)
41.61USD
1 Jul 2013
$0.27 (+0.65%)
$41.34
$41.40
$41.93
$41.07
4,589,412
6,300,085
$48.00
$32.51
ABBV.K
About
Overall
| Beta: | -- |
| Market Cap (Mil.): | $65,898.97 |
| Shares Outstanding (Mil.): | 1,583.73 |
| Dividend: | 0.40 |
| Yield (%): | 3.85 |
Financials
| ABBV.K | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 12.27 | 32.92 | 33.02 |
| EPS (TTM): | 3.39 | -- | -- |
| ROI: | 31.67 | 19.76 | 19.07 |
| ROE: | 71.43 | 20.57 | 20.00 |
BRIEF-Galapagos announces $50m extension to AbbVie deal
BRUSSELS, May 17 - Galapagos NV : * AbbVie and Galapagos extend GLPG0634 collaboration to include crohn's disease * Says AbbVie to pay Galapagos $50 million upon successful completion, expected
Abbvie says Chief Scientific Officer John Leonard to retire
- AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
Abbvie says Chief Scientific Officer John Leonard to retire
May 10 - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
AbbVie delivers on strong growth of Humira arthritis drug
- AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially lucrative new treatments for hepatitis C by early 2015.
UPDATE 3-AbbVie delivers on strong growth of Humira arthritis drug
April 26 - AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially lucrative new treatments for hepatitis C by early 2015.
AbbVie delivers on scorching Humira drug sales growth
- AbbVie Inc reported slightly better than expected quarterly results on Friday, fueled by surging sales of its Humira treatment for rheumatoid arthritis.
AbbVie meets expectations, fueled by Humira sales
April 26 - AbbVie Inc reported slightly better than expected quarterly results, fueled by surging sales of its Humira treatment for rheumatoid arthritis.
UPDATE 1-AbbVie hepatitis C drugs knock out virus at 8 weeks
* Bristol-Myers shares up 1.2 percent after promising data
AbbVie hepatitis C drugs knock out virus at eight weeks
- A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.
AbbVie hepatitis C drugs knock out virus at 8 weeks
April 23 - A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
